Pfizer accesses Seattle Genetics' empowered antibody platform in deal worth up to $208M
This article was originally published in Scrip
Executive Summary
Seattle Genetics appears to be steadily gaining respect in the pharma world for its Antibody-Drug Conjugate (ADC) technology, which delivers an anticancer on the back of an antibody.